When a product that has sold $3.4 billion without ever being on a shelf finally gets shelf space, the addressable market expands in a way that direct sales alone cannot replicate.
See for yourself whether the retail debut, the return to profitability, and the rebuilt omnichannel model make BODI worth adding to your portfolio before the May launch date arrives.
Smart Move (Sponsored)
Most retirement portfolios are heavily tied to stocks, bonds, and dollar-based funds.
When markets wobble, these assets often move together, putting your retirement at risk.
That’s why some investors are exploring physical gold and silver through a Gold IRA.
It’s a way to protect part of your retirement from market swings.
A free guide shows how rollovers work, how metals are stored, and what to know before adding them to your portfolio.
Preparation before volatility hits can make all the difference.
Get the guide here
Shakeology Is Going to Sprouts in May, and That Is a First in BODI’s History
The Beachbody Company, Inc. (NASDAQ: BODI) just dropped its best piece of news in years on the Q4 2025 earnings call.
Shakeology, which has sold $3.4 billion and racked up over a billion servings as a $129 direct-only product, is hitting Sprouts supermarkets for the first time ever in May.
Not a pilot. Not a soft test. A confirmed retail launch with a selling partner already presenting the BODI line to additional accounts.
A product that spent its whole life sold to motivated buyers is about to sit next to casual shoppers who have heard of Shakeology but never committed to a $129 subscription.
That is a new customer pool for BODI, and $3.4 billion in direct sales already proved demand exists.
Shakeology debuts at Sprouts in May, confirmed: This is not a maybe. It is on the BODI earnings call, the distribution partner is engaged, launch date is set.
New seven-serve format at $34.99 removes the biggest barrier: The $129 direct version required commitment. A $34.99 grab-and-go bag does not.
P90X supplements follow into grocery, drug and mass merchants in Q2: Multiple new retail channels opening for BODI at the same time, not just one door.
Sprouts is the proof of concept for BODI’s entire retail strategy. It works, and a wave of accounts follows. It stalls, and you get an early warning.
Action: Buy BODI before the May launch, not after. If Sprouts shows positive sell-through and Q2 retail accounts get confirmed, add immediately.
Rollout stalls or delays past Q2, trim and wait for confirmed accounts before rebuilding.
Watch Now (Sponsored)
It's critical for jet engines, steel, electric batteries, and AI chips.
Yet Russia, China, and Indonesia control 80% of its production.
Only ONE company in America can change that.
Here's why an ex-CIA economist believes the White House will invest in it in the days ahead... sending shares soaring.
Nine Straight Quarters of Positive EBITDA
Q4 2025 was BODI’s second consecutive quarter of net income and the ninth straight quarter of positive EBITDA.
It was also the first full-year operating profit since the 2021 IPO. BODI went public, lost money immediately, and quietly turned itself around while most people were watching other tickers.
The balance sheet cleaned up, too. BODI ended the year with $39 million in cash against $25 million in debt, which means you are buying a net cash business.
There is no secondary offering coming to fund the retail launch. BODI already has the money.
Nine consecutive quarters of positive adjusted EBITDA: That streak started during BODI’s messy restructuring and kept going, which tells you it is structural, not cosmetic.
Second straight quarter of actual net income, not adjusted: This is the real number, not a version of profitability BODI invented to look better.
Net cash of $39M vs $25M debt: More cash than debt means the retail launch gets funded without diluting BODI shareholders.
Profitability arrived at BODI while revenue was still falling. The cost base was rebuilt to work at a smaller level, so retail revenue lands on a business already covering its costs.
Action: Hold BODI while EBITDA stays positive and digital subscribers stabilize.
If both go negative in the same quarter retail launches, the core is shrinking faster than retail can fix, and you cut exposure immediately.
Rare Access (Sponsored)
For decades, one type of investment was reserved for the ultra-wealthy.
Then Executive Order 14330 changed everything — opening it up to ordinary investors.
Now you can access this booming opportunity for less than $20.
See what changed
P90X Generation Next Just Launched
P90X Generation Next launched in February, the first new version in fifteen years.
P90X built one of the most loyal fitness followings in direct-to-consumer history and had not had a new BODI release since the Obama administration.
A fresh program gives lapsed subscribers an actual reason to come back.
The win-back campaign targets over eight million former BODI subscribers. Most of them left because the MLM structure was annoying, not because the product was bad.
Reaching them now without the sales pressure costs BODI far less than finding cold traffic.
P90X Generation Next is already live, not coming soon: The program launched in February, and BODI’s marketing push is running now.
Eight million former BODI subscribers are warm leads, not strangers: These people already bought once. Winning them back costs far less than finding brand new customers.
New Shopify site launches in April, right before the retail rollout: A rebuilt direct commerce experience arrives just as BODI’s retail supplements hit shelves, so both channels open together.
None of this is future planning. The program is out. The campaign is active. Shopify is weeks away. You can watch each BODI milestone land in real time.
Action: On the Q2 earnings call, if BODI subscriber numbers improve quarter over quarter from win-back conversions or P90X uptake, add 15% to your position on the print.
That tells you organic growth is working on top of the retail launch, not instead of it.
Craig-Hallum Initiated BODI With a Buy Rating
On March 2, Craig-Hallum initiated BODI with a Buy and a $15 target while the stock was around $10.
For a small-cap turnaround that most analysts have ignored, that is a meaningful first step that puts the BODI story in front of institutional investors who were not paying attention.
It landed alongside nine consecutive profitable quarters, a confirmed retail launch, and a BODI EPS consensus revised over 200% higher.
Estimates got crushed during the restructuring, so even modest improvement looks like a massive beat. BODI is up 19% in four weeks, while consumer discretionary is down 7%.
Craig-Hallum Buy at $15 is the first major initiation on the BODI turnaround thesis: When the first analyst shows up with a serious price target, more tend to follow.
BODI EPS consensus revised over 200% higher for the current year: Estimates got hammered during the restructuring and are now playing catch-up fast.
BODI up 19% in four weeks while the sector bleeds 7%: Outperforming a weak group by that margin means something specific is working here.
Coverage alongside real catalysts makes BODI setups crowded fast. Right now, it is still early.
Action: If a second analyst initiates BODI with a target above $12 in the next 60 days, add 10% to your position before the broader audience arrives.
A second initiation with a target below $10 tells you the upside case is contested, and you hold flat.
The Omnichannel Rebuild Is What Makes BODI Different From the Old Business
Two years ago, BODI was a one-channel business. When the MLM network shrank, everything shrank with it.
The new BODI model runs five separate channels: direct-to-consumer, Amazon, retail, affiliates, and the win-back program. A bad quarter in one does not drag the others down.
Amazon Subscribe and Save is growing month over month and beating expectations without heavy management.
The affiliate structure replaced the old BODI MLM network after partner fees running into tens of millions annually were cut. Those savings are a big reason BODI’s profitability arrived.
Five acquisition channels now vs one before: BODI’s revenue concentration risk is lower than at any point in the company's history.
Amazon Subscribe and Save is growing month over month and beating expectations: Marketplace revenue is building itself without heavy operational overhead.
MLM partner fees eliminated, removing tens of millions from BODI’s annual cost base: That cash is now staying in the business instead of funding a sales structure that collapsed anyway.
That structure is what makes BODI’s retail launch lower risk than it sounds. Retail does not need to be perfect on day one.
Action: If BODI’s Amazon and direct-to-consumer channels combined show growth on the next quarterly print before retail contributes a dollar, size up to your full target allocation right then.
The omnichannel model proving itself without retail means you want full exposure before Q2 confirms retail is adding on top.
Trivia: What’s unusual about the Euro coins across countries?
The Risks Are Specific, and You Can Monitor Every Single One of Them
Getting BODI onto Sprouts shelves is step one, not the finish line. Products that earn shelf space still have to sell through or the retailer pulls them.
Shakeology has no retail sell-through history to benchmark against, so you are going into the BODI launch with strong brand recognition but no data.
Digital subscriptions fell 18.7% year over year in Q4 and need to flatten. If they keep falling faster than BODI retail grows, total revenue does not stabilize.
BODI retail sell-through data does not exist yet: You are betting on strong initial velocity with no benchmark to compare against.
BODI digital subscribers are down 18.7% year over year, and that trend needs to stop: Falling subscribers while launching retail means two things have to go right at once.
BODI revenue still declining through the MLM transition: Total revenue fell 40% in 2025 and needs a floor before it can grow.
Both are visible every quarter. You are not flying blind on BODI.
Action: Set your BODI stop at $8 before the May launch.
Any retail delay, distribution partner pullback, or quarterly subscriber decline that breaks BODI through $8 means the thesis timeline is in trouble, and you exit without waiting for confirmation.
Final Word: The First Rep Is Always the Hardest, and BODI Is Almost Done
The Sprouts launch in May is the representation of the whole thesis BODI depends on. It works, and more accounts follow across grocery, drug, mass merchant and club stores.
It stalls, and you have a clear exit with a number attached before you ever get there.
Nine straight profitable quarters, a rebuilt omnichannel model, a new P90X program already live, and eight million former customers being actively courted is not an accident.
Buy BODI before May, watch the first sell-through numbers, and let the shelves do the talking.
Setup Scorecard
Entry Window: Before the May Sprouts launch. The BODI catalyst is the launch itself, not the aftermath.
Catalyst Watch: BODI May Sprouts debut, Q2 retail account confirmations from Advantage Solutions, subscriber trend on next quarterly print, P90X Generation Next uptake data.
Upside Setup: Proven $3.4B brand entering retail for the first time. BODI's success at Sprouts unlocks grocery, drug, mass merchant and club stores on top of existing direct revenue.
Downside Cushion: Net cash position, nine consecutive positive BODI EBITDA quarters, and 87.3% digital gross margin mean the business does not break on one soft retail quarter.
What Moves It Next: BODI Sprouts sell-through velocity, additional account confirmations, and digital subscriber stabilization on the Q2 print.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
